Zevra Therapeutics (ZVRA) FCF Margin (2019 - 2026)
Zevra Therapeutics' (ZVRA) quarterly FCF Margin came in at 16.86% in Q1 2026, up 5765.0% YoY from 0.29% in Q1 2025, and up 3.86% on a QoQ basis from 16.23% in Q4 2025.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) FCF Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 8 years of FCF Margin data on file, last reported at 16.86% in Q1 2026.
- Quarterly FCF Margin rose 5765.0% year-over-year to 16.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.81% (up 16242.0% YoY) and the FY2025 annual result came in at 2.29%, up 29276.0% from the prior year.
- FCF Margin climbed to 16.86% in Q1 2026, from 16.23% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 16.86% in Q1 2026 to a low of 1167.81% in Q2 2022.
- A 5-year average of 229.32% and a median of 131.78% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin sank 130618 bps — and 2023, when it surged 106478 bps.
- Tracing ZVRA's FCF Margin over 5 years: stood at 198.66% in 2022, then soared by 37 bps to 125.62% in 2023, then fell by 8 bps to 135.28% in 2024, then soared by 112 bps to 16.23% in 2025, then increased by 4 bps to 16.86% in 2026.
- The last three FCF Margin figures came in at 16.86% (Q1 2026), 16.23% (Q4 2025), and 15.94% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | 42.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.36% |
| Mar 31, 2026 | 16.86% |
| Dec 31, 2025 | 16.24% |
| Sep 30, 2025 | 15.92% |
| Jun 30, 2025 | -14.73% |
| Mar 31, 2025 | -40.79% |
| Dec 31, 2024 | -135.28% |
| Sep 30, 2024 | -490.30% |
| Jun 30, 2024 | -429.51% |
| Mar 31, 2024 | -471.97% |
| Dec 31, 2023 | -125.62% |
| Sep 30, 2023 | -165.80% |
| Jun 30, 2023 | -103.03% |
| Mar 31, 2023 | -128.27% |
| Dec 31, 2022 | -198.66% |
| Sep 30, 2022 | -230.55% |
| Jun 30, 2022 | -316.85% |
| Mar 31, 2022 | -90.01% |
| Dec 31, 2021 | -33.50% |
| Sep 30, 2021 | -139.13% |